FDA Drug Safety Podcast: FDA warns of serious immune system reaction with seizure and mental health medicine lamotrigine (Lamictal)
On April 25, 2018, FDA warned that the medicine lamotrigine (brand name Lamictal) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body ’s infection-fighting immune system. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - April 30, 2018 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
MS: New Dosing, A New Withdrawal
Cutting the risk for natalizumab-related PML, update on disability outcomes with ibudilast, and daclizumab pulled from the global market. (Source: Medscape Pharmacists Podcast)
Source: Medscape Pharmacists Podcast - March 29, 2018 Category: Drugs & Pharmacology Authors: Medscape Source Type: podcasts
FDA Drug Safety Podcast: FDA review finds additional data supports the potential for increased long-term risks with antibiotic clarithromycin (Biaxin) in patients with heart disease
On February 22, 2018, FDA advised caution before prescribing the antibiotic clarithromycin (brand name Biaxin) to patients with heart disease because of a potential increased risk of heart problems or death that can occur years later. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - February 26, 2018 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA adds Boxed Warning to highlight correct dosing of Ocaliva (obeticholic acid) for patients with a rare chronic liver disease
On February 1, 2018 FDA is warning that the medicine Ocaliva (active ingredient obeticholic acid) has been incorrectly dosed daily instead of weekly in patients with moderate to severe primary biliary cholangitis (or PBC), a rare chronic liver disease, increasing the risk of serious liver injury. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - February 7, 2018 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA limits packaging for anti-diarrhea medicine Loperamide (Imodium) to encourage safe use
On January 30, 2018, to foster safe use of the over-the counter (or OTC) anti-diarrhea drug loperamide, FDA announced it is working with manufacturers to use blister packs or other single dose packaging and to limit the number of doses in a package. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - February 6, 2018 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
'Real World' CAR T Cells: Comparing and Using Approved Products
Drs Perales and Pasquini discuss the rapidly advancing field of CAR T and how patient safety and choice can be managed during these unprecedented times. (Source: Medscape Pharmacists Podcast)
Source: Medscape Pharmacists Podcast - February 2, 2018 Category: Drugs & Pharmacology Authors: Medscape Source Type: podcasts
FDA Drug Safety Podcast: FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older
On January 11, 2018, FDA announced that it is requiring safety labeling changes for prescription cough and cold medicines containing codeine or hydrocodone to limit the use of these products to adults 18 years and older because the risks of these medicines outweigh their benefits in children younger than 18. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - January 16, 2018 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
Hormone Therapy and Chronic Conditions: Let's Get Rational
Hormone therapy must be discussed and individualized for each patient in order to achieve the best outcome for treating menopause. (Source: Medscape Pharmacists Podcast)
Source: Medscape Pharmacists Podcast - January 4, 2018 Category: Drugs & Pharmacology Authors: Medscape Source Type: podcasts
FDA Drug Safety Podcast: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS)
On December 20, 2017, an Food and Drug Administration (FDA) review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - December 26, 2017 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA to evaluate increased risk of heart-related death and death from all causes with the gout medicine febuxostat (Uloric)
On November 15, 2017, FDA alerted the public that preliminary results from a safety clinical trial show an increased risk of heart-related death with febuxostat (brand name Uloric) compared to another gout medicine called allopurinol. We required the Uloric drug manufacturer, Takeda Pharmaceuticals, to conduct this safety study when we approved the medicine in 2009. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - November 20, 2017 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
Broad-Spectrum Antibiotics Reduce Hospital Mortality
Dr Andrew Shorr reports on promising data suggesting that broad-spectrum antibiotics reduce mortality, but will overly broad therapy cause antibiotic resistance? (Source: Medscape Pharmacists Podcast)
Source: Medscape Pharmacists Podcast - October 20, 2017 Category: Drugs & Pharmacology Authors: Medscape Source Type: podcasts
FDA Drug Safety Podcast: FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease
On September 21, 2017, FDA warned that the liver disease medicine Ocaliva (active ingredient obeticholic acid) is being incorrectly dosed in some patients with moderate to severe decreases in liver function, resulting in an increased risk of serious liver injury and death. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - October 4, 2017 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks
Based on our additional review, the U.S. Food and Drug Administration (FDA) is advising that the opioid addiction medications buprenorphine and methadone should not be withheld from patients taking benzodiazepines or other drugs that depress the central nervous system (CNS). (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - October 2, 2017 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
